Lam SY, et al. - In order to investigate the anticancer potential of metformin on metastatic prostate cancer, researchers performed this retrospective review. The patients had metastatic prostate cancer and were 281 in total, with a mean age of 70 ± 10. The significance of patients receiving metformin in addition to their current treatment was determined. Using PCWG3 and RECIST criteria, progression-free survival (PFS) was assessed. The evaluation of 6-month (6MO) PSA response and overall survival (OS) was also carried out. Lower risk of progression was observed in metformin users vs non-users in the metastatic hormone-sensitive prostate cancer group. A significantly higher risk of progression was evident among metformin users vs non-users within the metastatic castration resistant prostate cancer group. The estimated median overall survival was 81.5 months. Metformin groups showed a significant difference in survival time. Overall, findings revealed no significant differences in 6MO PSA response or PFS. In terms of OS, a significant difference was evident among patients who were included in the metformin group and those who were not.